Mammoth Biosciences, Inc.
http://mammoth.bio/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mammoth Biosciences, Inc.
Gene Therapy: What To Expect Now And In The Future
The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.
Gene Therapy: What To Expect Now And In The Future
The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.
Vertex Gains In Vivo CRISPR Foothold With Mammoth Pact
Deal Snapshot: The nearly $700m deal gives Vertex, already with a major foothold in CRISPR, access to Mammoth’s ultra-compact gene-editing technology in two diseases.
Mammoth Biosciences Thinks Ultra-Small As It Attains Elephant-Sized Valuation
The Jennifer Doudna-backed startup got a billion-dollar valuation with VC rounds totaling $195m. CEO Trevor Martin talked with Scrip about Mammoth’s ultra-small CRISPR system technology.
Company Information
- Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice